Your Search Returned 500 tagged news reports
The fully automated Smart-Max system, which has a touch screen interface, can be used for cell mixing, cooling, thawing, dilution, incubation and digestion. The Smart-Max system is used in tandem with the recently launched Sepax 2 system that can
Contact Information Available for logged-in reporters only Description Research from Rutgers Cancer Institute of New Jersey demonstrates that using zebrafish to identify self-renewing tumor stem cells in prostate cancers may be more beneficial than
Amanda Boxtel has not walked under her own power for more than 22 years. Teaching herself to step once again has been neither pretty nor cheap. Her first tentative strides are rarely accompanied by trumpet crescendos or the singing of angels. Instead,
It's a strategy reserved for people like Jason McIntyre whose form of MS is very aggressive and resistant to drug therapy. About three years ago, the Melbourne truck driver arrived home with blurry vision. He told his wife, Kym, that he couldn't read
Plant researchers at VIB and Ghent University have found that plants generally live longer than animals because they utilize their stem cells, which are crucial for the uninterrupted generation of new cells, better than animals.
Beyond Eggs is a plant-based egg substitute made out of peas, sorghum, and nine other plants. While it may sound gross, Hampton Creek claims its product is healthier, has a longer shelf-life, and costs 19 percent less than real eggs.
Bioheart therapies for the more than 36 million patients in Uganda. Bioheart will begin distributing MyoCell (muscle derived stem cells) and AdipoCell (adipose derived stem cells) for a variety of indications in Uganda. Bioheart chief science officer
Stem cell agency president to resign, return to Australia Alan Trounson will leave California stem cell research funding agency to spend more time with his family in Australia. Alan Trounson, the Australian biologist turned administrator of
Good stem cell companies will get the funding they need to bring their products to market, financial and medical executives said at this year's Stem Cell Meeting on the Mesa . Biotech companies continue to attract investor interest, speakers said at
A subsidiary of Australian company Mesoblast Ltd. has agreed to pay $50 million for the technology behind the drug and could receive up to $50 million more if the drug passes certain clinical trials and regulatory reviews, the companies said.